Alkermes Controlled Therapeutics Inc. has patented orexin OX2 receptor (OX2R) agonists reported to be useful for the treatment of cataplexy.

Novartis AG has identified triazolo-pyrimidine analogues acting as Werner syndrome ATP-dependent helicase (WRN) inhibitors reported to be useful for the treatment of cancer.

Nagasaki University and Shionogi & Co. Ltd. have synthesized quinolone compounds reported to be useful for the treatment of malaria.

Innocure Therapeutics Inc. has divulged piperidinediones as proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase cereblon (CRBN)-binding moiety covalently linked to bromodomain-containing protein 4 (BRD4)- and/or tyrosine-protein phosphatase non-receptor type 11 (PTPN11)-targeting moiety via linker reported to be useful for the treatment of cancer.

Halda Therapeutics Opco Inc. has patented proteolysis-targeting chimeric (PROTAC) compounds comprising an E3 ubiquitin ligase cereblon (CRBN)-binding moiety covalently bonded to a protein-targeting moiety via linker reported to be useful for the treatment of cancer and hepatitis.

Gilead Sciences Inc. has presented tetracyclic compounds reported to be useful for the treatment of Zika virus infection.

Roche has synthesized pyruvate dehydrogenase kinase 1 (PDK1) inhibitors reported to be useful for the treatment of systemic lupus erythematosus, psoriasis, inflammatory bowel diseases, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and cancer.

Blossomhill Therapeutics Inc. has identified macrocyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Nucmito Pharmaceuticals Co. Ltd. has disclosed indene derivatives reported to be useful for the treatment of cancer and fibrosis.

Sun Yat-Sen University has divulged pyrimidodiazepanone compounds reported to be useful for the treatment of depression.